bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

by Maria Zannes | Apr 17, 2025 | Press Releases

Process optimization enhances data acquisition and processing speed, lowers reagent costs, and maintains test performance for early lung cancer detection SAN ANTONIO, TX – (April 17, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company...

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

by Maria Zannes | Mar 31, 2025 | Press Releases

Increased Demand, Expanded Insurance Coverage Drive Record Growth  SAN ANTONIO, Texas (March 31, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage...

Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

by Maria Zannes | Mar 26, 2025 | Press Releases

Case Demonstrates Benefit of Integrating CyPath® Lung into Standard of Care for Patients Under Surveillance After Treatment for Previous Lung Cancer SAN ANTONIO, Texas (March 26, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a case study...

Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

by Maria Zannes | Mar 19, 2025 | Press Releases

Case Demonstrates CyPath® Lung’s Potential in Guiding Oncological Care SAN ANTONIO, Texas (March 19, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath® Lung’s real-time assessment of the lung...

Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

by Maria Zannes | Mar 13, 2025 | Press Releases

SAN ANTONIO, Texas (March 13, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced the release of physicians’ case studies showing the benefit to patients and their doctors of using CyPath® Lung, the Company’s noninvasive test for early detection of...

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

by Maria Zannes | Mar 6, 2025 | Press Releases

Proactive steps reinforce bioAffinity Technologies’ laser focus on accelerating CyPath® Lung sales growth in strategic national markets Decreases labor and overhead costs, including 38% workforce reduction in non-CyPath® Lung personnel at Company’s subsidiary...
« Older Entries
Next Entries »

Categories

  • Articles (27)
  • Events (38)
  • News (52)
  • Press Releases (122)
  • Publications (17)

Recent Posts

  • bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics May 28, 2025
  • bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer May 20, 2025
  • bioAffinity Technologies Reports First Quarter 2025 Results May 15, 2025
  • Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer May 8, 2025
  • bioAffinity Technologies Announces Closing of $3.25 Million Offering May 7, 2025

Learn About CyPath Lung

CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.